Invitation to second quarter and first half 2019 results presentation
Oslo, Norway, 20 August 2019 – PCI Biotech invites to a presentation of the company’s second quarter and first half 2019 results on Wednesday 28 August 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 28 August, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation […]
Extension of preclinical research collaboration agreement with a top-10 large pharma company
Oslo (Norway), 22 July 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company. The pharma company is one of the global leaders in nucleic acid therapeutics and the collaboration was initiated in September 2015. The aim of […]
PCI Biotech to present at IPA World Congress
Oslo, Norway, July 1, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present the company at the International Photodynamic Association (IPA) World Congress in Boston, US. PCI Biotech will be represented by Per Walday (CEO), Hans Olivecrona (CMO) and Anders Høgset (CSO) who […]